Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer - A cost-effective addition to the treatment sequence.

被引：0
|
作者：
Cameron, D. A.
Camidge, D. R.
Gait, C.
Hirsch, M.
机构：
[1] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Mapi Values, Cheshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [31] Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey
    Demirci, Umut
    Gokmen, Erhan
    Eralp, Yesim
    Gunduz, Seyda
    Goksu, Sema Sezgin
    Korkmaz, Taner
    Kostek, Osman
    Turhal, Serdar
    Paydas, Semra
    Topcu, Sevgi
    Cakar, Burcu
    Karabulut, Bulent
    Tanriverdi, Ozgur
    Karaca, Burcak
    Deniz, Gulhan Ipek
    Alan, Ozkan
    Turkoz, Fatma Paksoy
    Basaran, Gul
    CANCER RESEARCH, 2020, 80 (04)
  • [32] Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer
    Bauerfeind, Ingo
    Elling, Dirk
    Heinemann, Volker
    BREAST CARE, 2010, 5 : 13 - 15
  • [33] Treatment of Estrogen Receptor-Positive Breast Cancer
    Lumachi, F.
    Brunello, A.
    Maruzzo, M.
    Basso, U.
    Basso, S. M. M.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (05) : 596 - 604
  • [34] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [35] RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., etal.
    Telford, Claire
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (02)
  • [36] Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer
    Chen, Ya-Chi
    Yu, Jiajie
    Metcalfe, Ciara
    De Bruyn, Tom
    Gelzleichter, Thomas
    Malhi, Vikram
    Perez-Moreno, Pablo D.
    Wang, Xiaojing
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) : 515 - 529
  • [37] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 961 - 965
  • [38] Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.
    Tan, Pui San
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [40] Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer
    Bui, Kim Tam
    Willson, Melina L.
    Goel, Shom
    Beith, Jane
    Goodwin, Annabel
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (03):
12345